“There are a few extra hoops to jump through in order to prescribe buprenorphine [Suboxone], and extra DEA oversight that a lot of physicians don’t want to bother with,” Alicia Agnoli, MD, MPH, a family practice doctor at the University of California Davis, discussing why more physicians don’t seek permission to prescribe the drug..
“An 18.6-month median duration of response and a median PFS of 21 months — this is unprecedented.” Sumanta Pal, MD, of City of Hope in Duarte, California, responding to data from a clinical trial of axitinib (Inlyta) and pembrolizumab (Keytruda) for advanced renal cell cancer.
“The biggest change in EMS has been the loss of ‘it can’t happen here’ to ‘let’s be ready when it happens.'” — Corey Slovis, MD, of Vanderbilt University Medical Center, talking about how mass shootings have triggered changes for emergency medicine.
“FDA is investigating whether abuse or misuse is also increasing and if so, what should be done to address this problem.” — FDA Commissioner Scott Gottlieb, MD, discussing the agency’s concerns about gabapentinoids.
“This is a very serious illness, so I’ll take every ounce of prevention I can get.” — William Schaffner, MD, of Vanderbilt University School of Medicine, on the interim flu vaccine efficacy figures for this flu season.
“We get the best deals of any payer in the commercial market.” — Health and Human Services Secretary Alex Azar, JD, on drug costs under government programs.
“There is good evidence that this improves outcomes and is just as safe for patients.” — Seth Crockett, MD, of the University of North Carolina, on new guidelines recommending cholecystectomy as initial treatment in many patients with acute pancreatitis.